In vivo, in vitro and pharmacologic models of Parkinson's disease
Language English Country Czech Republic Media print-electronic
Document type Journal Article, Review
PubMed
30433804
DOI
10.33549/physiolres.933895
PII: 933895
Knihovny.cz E-resources
- MeSH
- Humans MeSH
- Disease Models, Animal * MeSH
- MPTP Poisoning chemically induced genetics metabolism pathology MeSH
- Oxidopamine toxicity MeSH
- Parkinson Disease genetics metabolism pathology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Oxidopamine MeSH
Parkinson's disease (PD), which is the second most common neurodegenerative disorder after Alzheimer's disease, is firstly defined after James Parkinson's report. It carries motor symptoms such as resting tremor, bradykinesia and rigidity of skeletal muscle and freezing of gait. Furthermore, non-motor symptoms such as cognitive and behavioral problems, besides sensory impairments are seen in the patients. However, they may also suffer from sleep disorders or autonomic dysfunction. Although there are some medications in order to symptomatic management, but unfortunately, scientist could not have found exact approaches to cure this disease. Hence, producing a model which can express the most pathophysiologic and behavioral aspects of the disease is a desire. In this paper, we aimed to describe the different models of Parkinson's disease in brief.
References provided by Crossref.org